找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Urologic Oncology; Multidisciplinary Ca Kelly L. Stratton,Alicia K. Morgans Book 2022 The Editor(s) (if applicable) and The Author(s), unde

[復(fù)制鏈接]
樓主: dabble
21#
發(fā)表于 2025-3-25 04:25:18 | 只看該作者
Book 2022ngly integrates radiation therapy to primary cancers, nodal beds, and even metastatic sites. The culmination of these advances has been the creation of multidisciplinary teams that expertly provide comprehensive care to patients with urologic cancers. This book provides the framework to create such
22#
發(fā)表于 2025-3-25 11:31:06 | 只看該作者
High-Risk Localized Prostate Cancer,egies including surgery, radiation, and systemic therapy to ensure the best care in a rapidly evolving field. In this chapter we will review treatment of high-risk localized prostate cancer emphasizing the major pieces of evidence which underlie high-risk prostate cancer management.
23#
發(fā)表于 2025-3-25 15:18:30 | 只看該作者
24#
發(fā)表于 2025-3-25 17:24:40 | 只看該作者
25#
發(fā)表于 2025-3-25 20:44:19 | 只看該作者
Bladder-Sparing Approaches to Treatment of Muscle-Invasive Bladder Cancer,literature describing oncologic outcomes, discussion of quality of life considerations, and description of treatment planning techniques for high-quality radiotherapy (RT) delivery. Ongoing randomized clinical trials (RCTs) of interest will be underscored throughout as they pertain to each aspect of treatment.
26#
發(fā)表于 2025-3-26 01:38:57 | 只看該作者
Creating a Multidisciplinary Clinic,ng this care model can be challenging as it requires significant administrative support and a substantial commitment from the participating physicians. This chapter is a guide for those starting a MDC of their own.
27#
發(fā)表于 2025-3-26 04:18:54 | 只看該作者
28#
發(fā)表于 2025-3-26 11:35:34 | 只看該作者
Immunotherapy for Metastatic Prostate Cancer,xicity remains an important consideration for all the work conducted so far. As more work is done to optimize immunotherapy in prostate cancer, future studies may need to extend their scope to immune cells outside of the T cell and perhaps beyond checkpoint inhibition.
29#
發(fā)表于 2025-3-26 12:44:02 | 只看該作者
30#
發(fā)表于 2025-3-26 17:46:27 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-17 21:18
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
临沂市| 柯坪县| 本溪市| 内黄县| 湘潭县| 许昌市| 瑞金市| 普兰店市| 辉南县| 锡林郭勒盟| 清镇市| 乐东| 内乡县| 天峨县| 铜梁县| 垫江县| 娱乐| 台中市| 确山县| 壶关县| 乐山市| 双辽市| 喜德县| 兴城市| 万宁市| 班戈县| 古田县| 彝良县| 卢湾区| 堆龙德庆县| 武隆县| 桑日县| 二连浩特市| 大英县| 庆安县| 双柏县| 潞城市| 清远市| 永宁县| 广州市| 丹寨县|